FDA Approves Carvykti for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

HORSHAM, PA (April 5, 2024)– Johnson& Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved Carvykti® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news